|
ISIN No
|
INE232I01014
|
BSE Code / NSE Code
|
532872 / SPARC
|
Book Value (Rs.)
|
40.61
|
Face Value
|
1.00
|
|
Bookclosure
|
30/09/2020
|
52Week High
|
289
|
EPS
|
47.86
|
P/E
|
4.17
|
|
Market Cap.
|
6478.75 Cr.
|
52Week Low
|
108
|
P/BV / Div Yield (%)
|
4.92 / 0.00
|
Market Lot
|
1.00
|
|
Security Type
|
Other
|
|
The company history sections lists out major chronological events that happened to the company.
| 2007 - Sun Pharma Advanced Research Co.Ltd was formed in the year 2007, with separation of India's leading specialty pharma company, Sun Pharmaceutical Industries Ltd, and its active projects in drug discovery and innovation into a new company. The parent company, Sun Pharma Industries Ltd continues to invest independently in generic research.
- Sun Pharma Advanced Research Company Ltd (SPARCL) had allotted 3,39,441 equity shares of Re 1 each to the bond-holders of Sun Pharma Industries Ltd (SPIL) on conversion of 5,500 foreign currency convertible bonds upon conversion.
- Balance Sheet along with the Profit and Loss Account for the year ended March 31, 2007 adopted and the Reports of Directors & Auditors thereon.
- Mr. Dilip S Shanghvi and Mr. Sudhir V Valia, re appointed as the Directors of the Company.
- According to the clause 10.2 of the scheme of arrangement of demerger, sanctioned by the High Court of Gujarat through its order dated March 01, 2007, issued on March 28, 2007 and as per supplementary Trust Deed dated may 18, 2007, the FCCB's holders of Sun Pharma Industries Ltd, are entitled for one equity share of Re 1 each of the company for every equity share of Rs.5 each of SPIL.
2011
- "Sun Pharma announces USFDA approval for DOCEFREZ (docetaxel) for Injection".
2012
-SPARC - Starhaler Device finalist at Medical Design Excellence Awards
-Sun Pharma Advanced Research Company Ltd Issues Rights in the Ratio of 1:7
2013
-SPARC to provide update on NCE & NDDS programs
2014
-SPARC Announces India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN)
2017
- SPARC has received a Complete Response Letter (CRL) from the USFDA for its New Drug Application (NDA) for Elepsia XRTM, Levetiracetam extended-release tablets 1000 mg and 1500 mg.
2018
-SPARC to provide progress on R&D Pipeline
-Sun Pharma and SPARC Announce US FDA Approval of XELPROS to Treat Open-angle Glaucoma or Ocular Hypertension
-SPARC Announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension
-Schr”dinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program
2019
-SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational
-HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
-SPARC Receives Orphan Drug Designation from the USFDA for SCO-088 for the Treatment of Patients with Chronic Myeloid Leukemia
-SPARC Enters into a Licensing Deal with CMS
-SPARC Enters into Licensing Agreement with Bioprojet to Acquire Exclusive Rights for Investigational Medicinal Product, SCD-044
2020
-Sun Pharma Advanced Research Company Ltd grant of an exclusive license to Tripoint Therapeutics LLC to commercialize ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg tablets in the USA.
-Sun Pharma Advanced Research Company Ltd got positive top-line results from its Phase 3 trial for its investigational drug, SDN-037, for the treatment of Inflammation and Pain associated with Ocular Surgery
-SPARC to Provide Update on Clinical Programs and R&D Pipeline
2021
-SPARC enters into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target
-Sun Pharma Advanced Research Company Ltd has entered into an agreement with Visiox Pharma LLC to grant exclusive worldwide rights for the development and commercialization of PDP-716 and SDN-037
2022
-Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US.
2023 -Entered into licensing agreement to acquire exclusive rights for SCD-153. -Formation of US subsidiary.
2025 -IND application for SPARC's first ADC `SBO-154' filed with USFDA
|